Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 20 Strength of evidence of pharmacotherapy for SAD

From: Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

Agent Level of evidence Agent Level of evidence
Antidepressants
SSRIs [58, 426429] 1 TCAs  
Escitalopram [430432] 1 Clomipramine [458, 459] 3
Fluvoxamine [433435] 1 Imipramine [460] 3 (-ve)
Fluvoxamine CR [436, 437] 1 MAOIs and RIMAs  
Paroxetine [431, 438444] 1 Phenelzine [384, 386, 418, 461, 462] 1
Sertraline [445448] 1 Moclobemide [417, 462466] 1*
Fluoxetine [382, 387, 449] 1* Other antidepressants  
Citalopram [450, 451] 2 Mirtazapine [467, 468] 1*
Paroxetine CR [452] 2 Bupropion SR [469] 3
Adjunctive paroxetine [453] 3   
SNRIs    
Venlafaxine XR [439, 441, 454, 255, 456] 1   
Duloxetine [457] 2   
Other therapies
Anxiolytics   Anticonvulsants  
    Benzodiazepines   Pregabalin [474, 475] 1
      Clonazepam [385, 470, 471] 1 Gabapentin [476, 477] 2
      Alprazolam [386] 2 Levetiracetam [478480] 2 (-ve)
      Bromazepam [472] 2 Divalproex [481] 3
      Adjunctive clonazepam [473] 2 (-ve) Tiagabine [477, 482] 3
   Topiramate [483] 3
Other treatments   Atypical antipsychotics  
Atenolol [461, 484] 1 (-ve) Olanzapine [493] 2
Buspirone [383, 485] 1 (-ve) Quetiapine [494, 495] 2 (-ve)
Atomoxetine [486, 487] 1* Adjunctive aripiprazole [496] 3
Propranolol [488] 2 (-ve) Adjunctive risperidone [271] 3
Selegiline [489] 3   
Pergolide [490] 3 (-ve)   
Adjunctive buspirone [491] 3   
Adjunctive pindolol [492] 2 (-ve)   
  1. *Conflicting data. CR = controlled release; MAOI = monoamine oxidase inhibitor; RIMA = reversible inhibitor of monoamine oxidase A; SNRI = serotonin–norepinephrine reuptake inhibitor; SR = sustained release; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; XR = extended release; (-ve) = negative.